Essex Investment Management Co. LLC reduced its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 38.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 182,503 shares of the company's stock after selling 113,050 shares during the period. Essex Investment Management Co. LLC owned 0.29% of Evolus worth $2,015,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. KBC Group NV acquired a new stake in Evolus in the fourth quarter valued at approximately $49,000. IFP Advisors Inc boosted its position in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after purchasing an additional 4,709 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Evolus during the 3rd quarter worth $132,000. Dynamic Technology Lab Private Ltd acquired a new position in Evolus during the 3rd quarter valued at about $191,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in Evolus in the third quarter valued at about $212,000. Hedge funds and other institutional investors own 90.69% of the company's stock.
Evolus Stock Performance
Shares of EOLS stock traded down $0.46 during mid-day trading on Thursday, reaching $12.96. The stock had a trading volume of 533,763 shares, compared to its average volume of 592,964. Evolus, Inc. has a 1-year low of $9.25 and a 1-year high of $17.82. The firm has a market cap of $824.09 million, a price-to-earnings ratio of -14.24 and a beta of 1.28. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The business's fifty day moving average is $13.06 and its 200-day moving average is $14.01.
Analyst Upgrades and Downgrades
EOLS has been the topic of a number of research analyst reports. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Evolus in a research note on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and issued a $27.00 target price on shares of Evolus in a research note on Wednesday, March 5th. Finally, Barclays upped their price target on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th.
Get Our Latest Stock Analysis on EOLS
Evolus Company Profile
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Stories
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
